<i>Candida albicans</i>targets that potentially synergize with fluconazole

Lu, Hui; Shrivastava, Manjari; Whiteway, Malcolm; Jiang, Yuanying

doi:10.1080/1040841x.2021.1884641

Cited by 50 publications

(36 citation statements)

References 152 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The in vitro fungicidal activity of AmpB and the in vitro fungistatic activity of fluconazole and caspofungin against C. albicans have been reported in the literature. ,− …”

Section: Resultsmentioning

confidence: 99%

Rational Design of an Antifungal Polyacrylamide Library with Reduced Host-Cell Toxicity

Schaefer

Pham

Brunke

et al. 2021

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

Life-threatening invasive fungal infections represent an urgent threat to human health worldwide. The limited set of antifungal drugs has critical constraints such as resistance development and/or adverse side effects. One approach to overcome these limitations is to mimic naturally occurring antifungal peptides called defensins. Inspired by their advantageous amphiphilic properties, a library of 35 synthetic, linear, ternary polyacrylamides was prepared by controlled/ living radical polymerization. The effect of the degree of polymerization (20, 40, and 100) and varying hydrophobic functionalities (branched, linear, cyclic, or aromatic differing in their number of carbons) on their antifungal activity was investigated. Short copolymers with a calculated log P of ∼1.5 revealed optimal activity against the major human fungal pathogen Candida albicans and other pathogenic fungal species with limited toxicity to mammalian host cells (red blood cells and fibroblasts). Remarkably, selected copolymers outperformed the commercial antifungal drug amphotericin B, with respect to the therapeutic index, highlighting their potential as novel antifungal compounds.

show abstract

“…The in vitro fungicidal activity of AmpB and the in vitro fungistatic activity of fluconazole and caspofungin against C. albicans have been reported in the literature. ,− …”

Section: Resultsmentioning

confidence: 99%

Rational Design of an Antifungal Polyacrylamide Library with Reduced Host-Cell Toxicity

Schaefer

Pham

Brunke

et al. 2021

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

show abstract

“…Second, Eno1 has transglutaminase activity and an ability to bind host plasminogen (PLG) and thus plays a key role in the invasion and virulence of C. albicans ( 23 – 25 ). Furthermore, the homozygous deletion of the ENO1 gene resulted in increased susceptibilities of C. albicans to frontline antifungal drugs, such as amphotericin B, FLC, miconazole, and voriconazole ( 21 , 26 ). Thus, targeting Eno1 may be useful for treating C. albicans infection.…”

Section: Introductionmentioning

confidence: 99%

Baicalein Acts against Candida albicans by Targeting Eno1 and Inhibiting Glycolysis

Zhang

et al. 2022

Microbiol Spectr

Self Cite

View full text Add to dashboard Cite

show abstract

“…FCZ has useful properties that make it the drug of choice, such as a wide spectrum of action, low cell toxicity compared to other antimycotics and high bioavailability. However, FCZ has a fungistatic action, inhibiting growth but not killing yeast cells, which can lead to the development of resistance [ 10 ].…”

Section: Introductionmentioning

confidence: 99%

Ethyl Acetate Fraction of Punica granatum and Its Galloyl-HHDP-Glucose Compound, Alone or in Combination with Fluconazole, Have Antifungal and Antivirulence Properties against Candida spp.

et al. 2022

View full text Add to dashboard Cite

Candidiasis is the most common fungal infection among immunocompromised patients. Its treatment includes the use of antifungals, which poses limitations such as toxicity and fungal resistance. Plant-derived extracts, such as Punica granatum, have been reported to have antimicrobial activity, but their antifungal effects are still unknown. We aimed to evaluate the antifungal and antiviral potential of the ethyl acetate fraction of P. granatum (PgEA) and its isolated compound galloyl-hexahydroxydiphenoyl-glucose (G-HHDP-G) against Candida spp. In silico analyses predicted the biological activity of G-HHDP-G. The minimum inhibitory concentrations (MIC) of PgEA and G-HHDP-G, and their effects on biofilm formation, preformed biofilms, and phospholipase production were determined. In silico analysis showed that G-HHDP-G has antifungal and hepatoprotective effects. An in vitro assay confirmed the antifungal effects of PgEA and G-HHDP-G, with MIC in the ranges of 31.25–250 μg/mL and 31.25 ≥ 500 μg/mL, respectively. G-HHDP-G and PgEA synergistically worked with fluconazole against planktonic cells. The substances showed antibiofilm action, alone or in combination with fluconazole, and interfered with phospholipase production. The antifungal and antibiofilm actions of PgEA and G-HHDP-G, alone or in combination with fluconazole, in addition to their effects on reducing Candida phospholipase production, identify them as promising candidates for therapeutics.

show abstract

Candida albicanstargets that potentially synergize with fluconazole

Cited by 50 publications

References 152 publications

Rational Design of an Antifungal Polyacrylamide Library with Reduced Host-Cell Toxicity

Rational Design of an Antifungal Polyacrylamide Library with Reduced Host-Cell Toxicity

Baicalein Acts against Candida albicans by Targeting Eno1 and Inhibiting Glycolysis

Ethyl Acetate Fraction of Punica granatum and Its Galloyl-HHDP-Glucose Compound, Alone or in Combination with Fluconazole, Have Antifungal and Antivirulence Properties against Candida spp.

Contact Info

Product

Resources

About